Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 19

ACCELERATING THE DEVELOPMENT OF CURATIVE MEDICINES WITH FUNCTIONAL IMMUNE PROFILING
References:
1. Szabo P, et al. Longitudinal profiling of respiratory and systemic
immune responses reveals myeloid cell-driven lung inflammation
in severe COVID-19. Immunity 54: 1-18, 2021.
2. Xie CB, et al. Complement-activated human endothelial cells stimulate
increased polyfunctionality in alloreactive T cells. American
Journal of Transplantation 2021.
3. McKenna K, et al. Mesenchymal stromal cell delivery of oncolytic
immunotherapy improves CAR-T cell antitumor activity. Molecular
Therapy 29: 1808-1820, 2021.
4. Simpson-Abelson M, et al. Iovance generation-2 tumour-infiltrating
lymphocyte (TIL) product is reinvigorated during the manufacturing
process. Presented at ESMO Virtual Congress September 19-21,
2020.
5. Diab A, et al. Progression-free survival and biomarker correlates of
response with BEMPEG plus NIVO in previously untreated patients
with metastatic melanoma: results from the PIVOT-02 study. Journal
for ImmunoTherapy of Cancer 2020.
6. Zhu H et al. Metabolic Reprogramming via Depletion of CISH in
Human iPSC-Derived NK Cells Promotes In Vivo Persistence and
Enhances Anti-tumor Activity. Cell Stem Cell 27: 1-14, 2020.
7. Parisi G, et al. Persistence of adoptively transferred T cells with a
kinetically engineered IL-2 receptor agonist. Nature Communications
11: 660, 2020
8. Li D, et al. Persistent Polyfunctional Chimeric Antigen Receptor T
Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular
Carcinomas in Mice. Gastroenterology 158: 2250-2265, 2020.
9. Zhou J, et al. CD8+ T-cell mediated anti-malaria protection induced
by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC
assay. Human Vaccines & Immunotherapeutics 13: 1625-1629, 2017.
YP7 CAR-T products for the treatment of patients with liver cancer.
GENengnews.com | 19
http://www.GENengnews.com

Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Table of Contents for the Digital Edition of Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 1
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 2
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 4
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 5
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 6
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 7
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 8
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 9
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 10
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 11
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 12
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 13
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 14
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 15
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 16
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 17
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 18
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 19
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 20
https://www.nxtbookmedia.com